Actively Recruiting
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
Led by JYAMS PET Research & Development Limited · Updated on 2026-02-20
316
Participants Needed
2
Research Sites
53 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to evaluate the efficacy and safety of \[18F\]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.
CONDITIONS
Official Title
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand and voluntarily sign informed consent
- Age 50 years or older, any gender
- Diagnosed with healthy volunteer status, mild cognitive impairment, or Alzheimer's disease according to clinical criteria
- Able to tolerate brain MRI and PET imaging examinations
- Women of childbearing potential must use effective contraception during and for 3 months after the study; male participants must agree to contraception during and for 3 months after the study
You will not qualify if you...
- Atypical Alzheimer's disease clinical phenotypes as defined by 2014 IWG-2 criteria
- Possible frontotemporal degeneration with progressive behavioral and language impairments
- Symptoms of Lewy body dementia including fluctuating cognition and Parkinsonian signs
- Significant mental illness or psychiatric symptoms interfering with imaging
- Brain abnormalities such as large strokes or space-occupying lesions seen on MRI
- Claustrophobia or inability to tolerate imaging procedures
- History of alcohol or drug abuse or dependency
- Hypersensitivity to the investigational drug or its components
- Currently pregnant or breastfeeding
- Received investigational Alzheimer's or dementia treatments within specified recent time frames
- Serious infectious, endocrine, metabolic, cardiac, liver, lung, or kidney diseases
- Conditions or medications causing QT interval prolongation
- Any other conditions judged by researchers as unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China, 430000
Not Yet Recruiting
2
Huashan Hospital of Fudan University
Shanghai, Province, China, 201199
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here